biotech
CytomX Therapeutics Inc reported favourable results for its ongoing trial of CX-904 on Thursday. Shares of the biotech firm are still down about 30% at writing. CX-901 shows favourable safety profileThe PROBODY T-cell engager showed anti-cancer properties in a Phase 1a clinical study of patients with advanced pancreatic cancer. CX-904 has an adequate safety profile as well to be administered in an outpatient setting, as per the press release on Thursday. The data “opens broad new possibilities for T-cell engagers across many targets and cancer types”, Sean McCarthy – the chief executive of Cyt...
Invezz
Google DeepMind has introduced the third iteration of its groundbreaking artificial intelligence model, AlphaFold, aimed at enhancing the efficiency and precision of drug design and disease treatment. This latest development was announced in London on May 8, marking a significant step forward in the use of AI in molecular biology. Comprehensive mapping of life’s moleculesSince its initial breakthrough in 2020, where AlphaFold utilized AI to predict protein behaviors, the tool has evolved. The current version, developed in collaboration with Isomorphic Labs—both companies under the leadership o...
Invezz
The iShares Russell 2000 ETF (IWM) has continued to underperform its bigger rivals like the SPDR S&P 500 ETF (SPY) and the Invesco QQQ (QQQ) ETFs. It has risen by just 2.2% this year while the other two have soared by over 5%. This is a trend that has been going on for a long time as mega-cap companies like Apple, Amazon, Nvidia, and Alphabet have continued soaring. The Russell 2000 index is mostly made up of smaller companies with thinner balance sheets and profitability. IWM vs SPY vs QQQ ETFs Best-performing Russell 2000 ETF stocksStill, the index has had some of the best-performing compani...
Invezz
Ocugen (NASDAQ: OCGN) stock price has launched higher since last year, helped by the rising hopes that OCU400 will be approved by the Food and Drug Administration (FDA). The stock surged by over 378% from its lowest point in September and by 183% this year. OCU400 could be a gamechangerOcugen is a biotech company that gained popularity during the Covid-19 pandemic as it worked on OCU500, a Covid vaccine. At the time, its stock surged to a high of $17.46, giving it a market valuation of over $12 billion. Now, the focus among investors has turned to OCU400, a new drug that will treat a rare cond...
Invezz
San José (United States) (AFP) - Elizabeth Holmes's startup Theranos made her a multi-billionaire hailed as the next US tech visionary by age 30, but it all evaporated in a flash of lawsuits, ignominy and, finally, an 11-year prison sentence on Friday. The rise and fall of Holmes, who in January was convicted of defrauding investors of her biotech startup, is a heavily chronicled saga that prompted a hard look at her methods but also the unseemly aspects of startup life. In many ways Holmes fit the image of a Silicon Valley entrepreneur, from her dark-colored turtleneck sweaters that evoked te...
AFP
- Bintai Kinden acquires 5.03% stake in MGRC- Newly redesignated Executive Director, Azri Azerai, to spearhead both companies' growth strategies PETALING JAYA, MALAYSIA, Feb 17, 2022 - (ACN Newswire) - Malaysian Genomics Resource Centre Berhad ("MGRC" or "the Group"), a leading genomics and biopharmaceutical specialist, is pleased to announce the entry of a new substantial shareholder, Bintai Kinden Corporation Berhad ("Bintai Kinden"), a specialist in mechanical and electrical engineering services to the construction sector, in the Group. Bintai Kinden now has an effective shareholding of 5.0...
ACN Newswire
- Group swings back to profitability on distribution of immunotherapy treatment- Redesignation of Noor Azri bin Dato' Sri Noor Azerai as Executive Director PETALING JAYA, MALAYSIA, Feb 16, 2022 - (ACN Newswire) - Malaysian Genomics Resource Centre Berhad ("MGRC" or "the Group"), a leading genomics and biopharmaceutical specialist, today announced that it recorded revenue of RM7.63 million for the second quarter ended 31 December 2021 ("2Q FY2022"), a significant increase of RM7.49 million compared with revenue of RM0.14 million for the corresponding quarter of the previous year. The increase i...
ACN Newswire
ADELAIDE, AUS, Jan 5, 2022 - (ACN Newswire) - TrialWire(TM) is pleased to announce new B-cell lymphoma clinical studies are now available on the TrialWire Platform. More than 6 million people have used TrialWire over the past few years to find clinical trials that are right for them at clinics and specialist centers near them. The studies on TrialWire are available in Australia, New Zealand, and the U.S. They include new therapies in research for relapsed B-cell lymphoma run by leading lymphoma specialists. You can search for a study near you and find your local specialist team here. https://w...
ACN Newswire
ADELAIDE, AUS, Jan 5, 2022 - (ACN Newswire) - TrialWire(TM) is pleased to announce new Autism (ASD) clinical studies are now available on the TrialWire Platform. More than 6 million people have used TrialWire over the past few years to find clinical trials that are right for them at clinics and specialist centers near them. The ASD studies on TrialWire are available in Australia, New Zealand, and the U.S. They include studies for children, teenagers and adults around ASD possible causes, and managing symptoms that can impact people's lives. You can search for a study near you and find your loc...
ACN Newswire
Foster City, CA, and Hangzhou, China, Jan 4, 2022 - (ACN Newswire) - Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced that Guo-Liang Yu, PhD, Co-Founder, Chairman and Chief Executive Officer of Apollomics, was recently appointed to Chairman of the Board for the BayHelix Group, effective January 2022. "I am honored to be selected by my peers to help guide the BayHelix Group as it continues to foster biotech innovations and expand business opportunities within the broad life sciences ...
ACN Newswire
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら